Home » Newsletters » BioWorld Science

BioWorld Science

March 4, 2002

View Archived Issues

Radiopharmaceutical therapy reduces pain with low toxicity in osteosarcoma patients

Effects on dendritic cell function of the immunomodulator R-848

Topical application of NF-kB decoy ODN successfully treats atopic dermatitis

Effective, safe, rapid and long-lasting relief of allergic symptoms achieved with tecastemizole

GI safety of Merck's new-generation COX-2-selective agent etoricoxib

Aventis reflects on achievements in 2001

Hepatoprotective effects of iNOS inhibitor Ono-1714 demonstrated in pig I/R model

PDE5 inhibitor reduces elevated lower esophageal sphincter tone in humans

Encouraging results obtained for Vasogen's immune modulation therapy in CHF

Corixa's Melacine phase III design approved

D-Pharm earns first milestone payment for SPD-421 from Shire

Endostatin designated orphan drug in malignant metastatic melanoma

Inhaled antimicrobial agent to be screened for potential against anthrax

OrBec receives orphan drug status in Europe for intestinal graft-vs.-host disease

NDA filed for Zomig Nasal Spray

Achillion initiates phase II trial of ACH-126443 in HBV

Oxigene and Peregrine conclude Arcus Therapeutics joint venture

Procleix HIV-1/HCV NAT assay approved in U.S.

Potential of new arthroscopy drug validated in phase II clinical trials

Scientists at Genentech describe c-mpl agonist antibodies

Tetracycline compounds with antibacterial activity

Compounds for use in diseases associated with hypercholesterolemia described by BASF

Histamine H3 receptor ligands reportedly useful for Alzheimer's disease, etc.

Italian researchers identify compounds with potential in the treatment of HCV infection

Factor Xa and/or factor VIIa inhibitors in the Merck pipeline

Roche synthesizes prodrugs of 4-phenylpyridine tachykinin NK1 receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...